Bartosz Hudzik/LinkedIn
Feb 11, 2026, 16:08
Bartosz Hudzik: Clinical Trials to Watch in 2026 – A Cardiovascular Lens
Bartosz Hudzik, Editorial Consultant at JACC Case Reports, shared on LinkedIn:
“Clinical trials to watch in 2026 — a cardiovascular lens
Nature Medicine highlights 11 trials poised to shape medicine in 2026. In cardiology, two stand out:
- Ziltivekimab – targeting the IL-6 inflammatory pathway to reduce residual inflammatory risk in atherosclerosis and CKD, moving beyond lipid-only prevention.
- Pelacarsen – a first-in-class antisense therapy for lipoprotein(a), tackling one of the most important genetically driven and previously untreatable CV risk factors.
Both are Phase 3 programs with the potential to redefine precision prevention.
2026 may be the year cardiovascular medicine shifts from risk markers to causal, target-specific therapies.”
More posts featuring Bartosz Hudzik on Hemostasis Today.
-
Oct 4, 2026, 15:06Vasiliki Gkalea: Journal of Clinical Medicine Launches Special Issue on Hematologic Thrombosis and Bleeding
-
Oct 4, 2026, 14:55Quentin Brebant: What Defines a High-Quality Red Blood Cell Concentrate?
-
Oct 4, 2026, 14:47Rana Al-Hrout: Recognizing Non-Anemic Iron Deficiency – Why Iron Matters Beyond Hemoglobin
-
Oct 4, 2026, 14:41David McIntosh: International Plasma Awareness Week 2026 – Closing the Global Plasma Gap
-
Oct 4, 2026, 14:33Pete Stibbs: CleanerVac Real-World Study Presented at VIVA and The VEINS 2026
-
Oct 4, 2026, 13:56Maria Elisa Mancuso: EHC 2026 Highlights the Unmet Needs of Women with Bleeding Disorders
-
Oct 4, 2026, 13:53Nirmal Shaji George: Individualizing Anticoagulation in Complex APS and Thrombocytopenia
-
Oct 4, 2026, 13:5210 Posts Not to Miss This Week
-
Oct 4, 2026, 13:45Suswapna Singh Rawat: The Clinical Significance of Coronary Plaque Stability